Disease-Modifying Drugs for Multiple Sclerosis Must Be Globally Available According to Therapeutic Guidelines Suitable to Different Regions of the World
AuthID
P-00J-2EE
P-00J-2EE
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service